ArticleBlood2019
CDK6 coordinates
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- CDK6 inactivation counteracts CALR-mutant-induced MPN evolution and sensitizes MPN stem cells to interferon-α treatment.HemaSphere · 2026Article
- Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.Therapeutic advances in hematology · 2026Article
- Article
- ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer.Journal of cellular physiology · 2025Article
- Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy.Frontiers in oncology · 2025Article
- Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.Blood · 2024Article
- Deregulation of the p19/CDK4/CDK6 axis in Jak2Leukemia · 2024Article
- Review
- Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.Haematologica · 2023Article
- Putative Role of Neutrophil Extracellular Trap Formation in Chronic Myeloproliferative Neoplasms.International journal of molecular sciences · 2023Review
- Recent advances in therapies for primary myelofibrosis.Faculty reviews · 2023Review
- CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.Molecular cancer · 2022Article
- Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.Cancers · 2022Review
- Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.International journal of molecular sciences · 2022Review
- Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.Haematologica · 2021Article
- CDK6 Is a Therapeutic Target in Myelofibrosis.Cancer research · 2021Article
- Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.Journal of cellular and molecular medicine · 2021Article
- A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation.Blood advances · 2021Article
- Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Iris Z UrasInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0002-2434-2756
Barbara MaurerInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Harini NivarthiCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-5545-5673
Philipp JodlInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Karoline KollmannInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0002-7937-4245
Michaela Prchal-MurphyInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Jelena D Milosevic FeenstraLudwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-7420-3298
Markus ZojerInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Sabine LaggerInstitute of Pathology and Forensic Veterinary Medicine, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0002-3032-9910
Reinhard GrausenburgerInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
Beatrice GrabnerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Raimund HollyCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Anoop KavirayaniVienna Biocenter Core Facilities, Histopathology Facility, Vienna, Austria; and.ORCID 0000-0003-2673-5040
Christoph BockCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0001-6091-3088
Heinz GisslingerLudwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria.
Peter ValentLudwig Boltzmann Institute for Hematology & Oncology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-0456-5095
Robert KralovicsCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0002-6997-8539
Veronika SexlInstitute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.ORCID 0000-0001-9363-0412
University of Veterinary Medicine Vienna · ATAustrian Academy of Sciences · ATComprehensive Cancer Center Vienna · ATMedical University of Vienna · ATVienna Biocenter · AT
Funding
Austrian Science Fund FWF P 30041
Abstract
Over 80% of patients with myeloproliferative neoplasms (MPNs) harbor the acquired somatic
Indexed as
ApoptosisMutationCyclin-Dependent Kinase 6HumansJanus Kinase 2Myeloproliferative DisordersNeoplasmsNF-kappa BSignal TransductionCDK6 protein, humanCyclin-Dependent Kinase 6JAK2 protein, humanJanus Kinase 2NF-kappa B
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.